Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
divalproex/paliperidone · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | divalproex sodium ER/paliperidone ER Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12 |
| Name | Type | Description |
|---|---|---|
| divalproex sodium ER/paliperidone ER | DRUG | Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12 |
Inclusion Criteria: * Have a diagnosis of schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) * Is clinically stable with no psychiatric hospitalization or change in existing mood stabilizers, antipsychotic, or an...
Divalproex/paliperidone is an investigational small-molecule combination being studied for use in schizophrenia. It is currently in Phase 1 clinical development. The drug is not approved and remains under investigation for this psychiatric condition.
Divalproex/paliperidone is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The combination is in early-stage clinical development for schizophrenia.
Divalproex/paliperidone is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 study has been completed as part of its early development program.
Divalproex/paliperidone has one completed clinical trial, NCT01094249, a Phase 1 drug interaction study of valproic acid and paliperidone extended-release in patients with schizophrenia, bipolar I disorder, or schizoaffective disorder. The study enrolled 9 participants in the United States.
Divalproex/paliperidone refers to a combination of valproic acid and paliperidone extended-release, as studied in clinical trial NCT01094249. The trial investigated the drug interaction between these two components in patients with schizophrenia and related psychiatric disorders.